Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA2DS2-VASc Score 0–1: A Korean Multi-Center Cohort
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Atrial fibrillation (AF) patients with low to intermediate risk, defined as non-gender CHA2DS2-VASc score of 0–1, are still at risk of stroke. This study verified the usefulness of ABCD score [age (≥60 years), B-type natriuretic peptide (BNP) or N-ter minal pro-BNP (≥300 pg/mL), creatinine clearance (<50 mL/min/1.73 m2), and dimension of the left atrium (≥45 mm)] for stroke risk stratification in non-gender CHA2DS2-VASc score 0–1. Materials and Methods: This multi-center cohort study retrospectively analyzed AF patients with non-gender CHA2DS2-VASc score 0–1. The primary endpoint was the incidence of stroke with or without antithrombotic therapy (ATT). An ABCD score was validated. Results: Overall, 2694 patients [56.3±9.5 years; female, 726 (26.9%)] were followed-up for 4.0±2.8 years. The overall stroke rate was 0.84/100 person-years (P-Y), stratified as follows: 0.46/100 P-Y for an ABCD score of 0; 1.02/100 P-Y for an ABCD score ≥1. The ABCD score was superior to non-gender CHA2DS2-VASc score in the stroke risk stratification (C-index=0.618, p=0.015; net reclassi fication improvement=0.576, p=0.040; integrated differential improvement=0.033, p=0.066). ATT was prescribed in 2353 patients (86.5%), and the stroke rate was significantly lower in patients receiving non-vitamin K antagonist oral anticoagulant (NOAC) ther apy and an ABCD score ≥1 than in those without ATT (0.44/100 P–Y vs. 1.55/100 P-Y; hazard ratio=0.26, 95% confidence interval 0.11–0.63, p=0.003). Conclusion: The biomarker-based ABCD score demonstrated improved stroke risk stratification in AF patients with non-gender CHA2DS2-VASc score 0–1. Furthermore, NOAC with an ABCD score ≥1 was associated with significantly lower stroke rate in AF pa tients with non-gender CHA2DS2-VASc score 0–1.
Abstract
Purpose: Atrial fibrillation (AF) patients with low to intermediate risk, defined as non-gender CHA2DS2-VASc score of 0–1, are still at risk of stroke. This study verified the usefulness of ABCD score [age (≥60 years), B-type natriuretic peptide (BNP) or N-ter minal pro-BNP (≥300 pg/mL), creatinine clearance (<50 mL/min/1.73 m2), and dimension of the left atrium (≥45 mm)] for stroke risk stratification in non-gender CHA2DS2-VASc score 0–1. Materials and Methods: This multi-center cohort study retrospectively analyzed AF patients with non-gender CHA2DS2-VASc score 0–1. The primary endpoint was the incidence of stroke with or without antithrombotic therapy (ATT). An ABCD score was validated. Results: Overall, 2694 patients [56.3±9.5 years; female, 726 (26.9%)] were followed-up for 4.0±2.8 years. The overall stroke rate was 0.84/100 person-years (P-Y), stratified as follows: 0.46/100 P-Y for an ABCD score of 0; 1.02/100 P-Y for an ABCD score ≥1. The ABCD score was superior to non-gender CHA2DS2-VASc score in the stroke risk stratification (C-index=0.618, p=0.015; net reclassi fication improvement=0.576, p=0.040; integrated differential improvement=0.033, p=0.066). ATT was prescribed in 2353 patients (86.5%), and the stroke rate was significantly lower in patients receiving non-vitamin K antagonist oral anticoagulant (NOAC) ther apy and an ABCD score ≥1 than in those without ATT (0.44/100 P–Y vs. 1.55/100 P-Y; hazard ratio=0.26, 95% confidence interval 0.11–0.63, p=0.003). Conclusion: The biomarker-based ABCD score demonstrated improved stroke risk stratification in AF patients with non-gender CHA2DS2-VASc score 0–1. Furthermore, NOAC with an ABCD score ≥1 was associated with significantly lower stroke rate in AF pa tients with non-gender CHA2DS2-VASc score 0–1.
참고문헌 (41)
- Wolf PA, "Atrial fibrillation as an independent risk factor for stroke : the Framingham Study", Stroke, 22, pp.983~988 (1991)
- Atrial Fibrillation Investigators, "Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials", Arch Intern Med, 154, pp.1449~1457 (1994)
- Bassand JP, "Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation : results from the GARFIELDAF registry", Blood Adv, 5, pp.1081~1091 (2021)
- Burdett P, "Atrial fibrillation in the UK : predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs", Eur Heart J Qual Care Clin Outcomes, 8, pp.187~194 (2022)
- Chao TF, "2021 focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society(APHRS)on stroke prevention in atrial fibrillation", J Arrhythm, 37, pp.1389~1426 (2021)
- January CT, "2019 AHA", ACC, ACC, pp.HRS guideline for the management of patients with atrial fibrillation : a report of the American College of Cardiology, American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society[DOI]
- Lip GYH, "Antithrombotic therapy for atrial fibrillation : CHEST guideline and expert panel report", Chest, 154, pp.1121~1201 (2018)
- Hindricks G, "2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS) : the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC", Eur Heart J, 42, pp.373~498 (2021)
- Shin SY, "Identification of markers associated with development of stroke in"clinically lowrisk"atrial fibrillation patients", J Am Heart Assoc, 8, pp.e012697~ (2019)
- Zathar Z, "Atrial fibrillation in older people: concepts and controversies", Front Med (Lausanne), 6, pp.175~ (2019)
- Atrial Fibrillation Investigators, "Echocardiographic predictors of stroke in patients with atrial fibrillation : a prospective study of 1066 patients from 3 clinical trials", Arch Intern Med, 158, pp.1316~1320 (1998)
- Hijazi Z, "N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation : insights from the ARISTOTLE trial(apixaban for the prevention of stroke in subjects with atrial fibrillation)", J Am Coll Cardiol, 61, pp.2274~2284 (2013)
- Piccini JP, "Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation", Circulation, 127, pp.224~232 (2013)
- Hijazi Z, "The ABC(age, biomarkers, clinical history)stroke risk score : a biomarker-based risk score for predicting stroke in atrial fibrillation", Eur Heart J, 37, pp.1582~1590 (2016)
- Nielsen PB, "Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation : should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?", Circulation, 137, pp.832~840 (2018)
- Lip GY, "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the Euro Heart Survey on atrial fibrillation", Chest, 137, pp.263~272 (2010)
- Rost NS, "Brain natriuretic peptide predicts functional outcome in ischemic stroke", Stroke, 43, pp.441~445 (2012)
- Shibazaki K, "Plasma brain natriuretic peptide can be a biological marker to distinguish cardioembolic stroke from other stroke types in acute ischemic stroke", Intern Med, 48, pp.259~264 (2009)
- Cockcroft DW, "Prediction of creatinine clearance from serum creatinine", Nephron, 16, pp.31~41 (1976)
- Lang RM, "Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", Eur Heart J Cardiovasc Imaging, 16, pp.233~271 (2015)
- Charitos EI, "A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence : insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions", Circulation, 126, pp.806~814 (2012)
- Calkins H, "2017 HRS", EHRA, APHRS, pp.SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, Europace[DOI]
- Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- Schulman S, "Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients", J Thromb Haemost, 3, pp.692~694 (2005)
- Austin PC, "Variance estimation when using propensityscore matching with replacement with survival or time-to-event outcomes", Stat Med, 39, pp.1623~1640 (2020)
- DeLong ER, "Comparing the areas under two or more correlated receiver operating characteristic curves : a nonparametric approach", Biometrics, 44, pp.837~845 (1988)
- Pencina MJ, "Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers", Stat Med, 30, pp.11~21 (2011)
- Kerr KF, "Evaluating the incremental value of new biomarkers with integrated discrimination improvement", Am J Epidemiol, 174, pp.364~374 (2011)
- RuffCT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
- Banerjee A, "Net clinical benefit of new oral anticoagulants(dabigatran, rivaroxaban, apixaban)versus no treatment in a ‘real world’ atrial fibrillation population : a modelling analysis based on a nationwide cohort study", Thromb Haemost, 107, pp.584~589 (2012)
- Friberg L, "Net clinical benefit of warfarin in patients with atrial fibrillation : a report from the Swedish atrial fibrillation cohort study", Circulation, 125, pp.2298~2307 (2012)
- Fauchier L, "Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?", Stroke, 47, pp.1831~1836 (2016)
- Kim TH, "Age threshold for ischemic stroke risk in atrial fibrillation", Stroke, 49, pp.1872~1879 (2018)
- Vinereanu D, "Echocardiographic risk factors for stroke and outcomes in patients with atrial fibrillation anticoagulated with apixaban or warfarin", Stroke, 48, pp.3266~3273 (2017)
- Inoue YY, "Quantitative tissue-tracking cardiac magnetic resonance(CMR)of left atrial deformation and the risk of stroke in patients with atrial fibrillation", J Am Heart Assoc, 4, pp.e001844~ (2015)
- Kim HK, "The East Asian paradox : an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease", Thromb Haemost, 121, pp.422~432 (2021)
- Lip GY, "Clinical and economic implications of apixaban versus aspirin in the low-risk nonvalvular atrial fibrillation patients", Stroke, 46, pp.2830~2837 (2015)
- Noseworthy PA, "Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation", Chest, 150, pp.1302~1312 (2016)
- Lip GYH, "The ABC pathway : an integrated approach to improve AF management", Nat Rev Cardiol, 14, pp.627~628 (2017)
- Yoon M, "Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC(atrial fibrillation better care)pathway for integrated care management : a nationwide cohort study", Thromb Haemost, 119, pp.1695~1703 (2019)
- Romiti GF, "Adherence to the ‘atrial fibrillation better care’pathway in patients with atrial fibrillation : impact on clinical outcomes—a systematic review and meta-analysis of 285, 000 patients", Thromb Haemost, 122, pp.406~414 (2022)